Conduit Pharmaceuticals Inc. has filed Supplement No. 1 to the definitive proxy statement for its 2024 virtual annual meeting of stockholders with the U.S. Securities and Exchange Commission. This filing, dated October 28, 2024, includes amendments to correct scrivener's errors in two paragraphs related to corporate governance and director independence. The company's board has affirmed that all directors, except for three named individuals, meet the independence criteria set by Nasdaq listing standards. Currently, the board has an equal number of independent and non-independent members due to a recent resignation. The board is actively seeking to appoint an additional independent director by December 18, 2024, to comply with Nasdaq's requirement for the Audit Committee composition. The proxy materials for the annual meeting are available online for stockholders.

Conduit Pharmaceuticals Inc. has filed Supplement No. 1 to the definitive proxy statement for its 2024 virtual annual meeting of stockholders with the U.S. Securities and Exchange Commission. This filing, dated October 28, 2024, includes amendments to correct scrivener's errors in two paragraphs related to corporate governance and director independence. The company's board has affirmed that all directors, except for three named individuals, meet the independence criteria set by Nasdaq listing standards. Currently, the board has an equal number of independent and non-independent members due to a recent resignation. The board is actively seeking to appoint an additional independent director by December 18, 2024, to comply with Nasdaq's requirement for the Audit Committee composition. The proxy materials for the annual meeting are available online for stockholders.